Antimesothelin Vaccine Crs-207 Plus Chemotherapy As Front-Line Treatment For Malignant Pleural Mesothelioma (Mpm).

7532 Background: CRS-207 is live-attenuated Listeria monocytogenes engineered to express the tumor-associated antigen mesothelin which is highly expressed in malignant pleural mesothelioma (MPM). CRS-207 stimulates potent innate and adaptive cellular immunity. Chemotherapy may act synergistically in combination with CRS-207 by altering the tumor environment to be more susceptible to immune-mediated killing. Methods: Key eligibility criteria included patients who were chemotherapy-naive, had unresectable MPM, good performance status (ECOG 0 or 1) and adequate organ function. Eligible patients received 2 prime vaccinations with CRS-207 (1 × 109 CFU; 250 mL IV over 2 hours) 2 weeks apart, followed by up to 6 cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) 3 weeks apart and 2 CRS-207 boost vaccinations 3 weeks apart. Subjects were followed every 8 weeks until disease progression. Clinically stable patients could continue CRS-207 maintenance vaccinations every 8 weeks. Objectives of the study were sa...